Clinical Trial

Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine

Study acronym: ATOM

Recruiting

Record status

This record was last updated March 18, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Summary

The investigators aim to assess and compare neurophysiological and biochemical changes induced by a 3-month treatment with atogepant (60 mg daily) in patients with high-frequency episodic migraine (8-14 monthly migraine days). Evaluations will include neurophysiological assessments (High-Density EEG, nociceptive reflexes, and visual evoked potentials) and biomolecular profiling (gene expression of endocannabinoid catabolizing enzymes, CGRP and PACAP plasma levels, and headache-specific microRNAs). Outputs will contribute to defining predictors of atogepant response, elucidating its effects on brain connectivity, excitability, and CGRP/endocannabinoid pathways, and identifying alternative therapeutic targets for non-responders.

Trial Details

NCT Number	NCT06882122
Lead Sponsor	IRCCS National Neurological Institute "C. Mondino" Foundation
Conditions	Migraine Disorder, Episodic Migraine
Enrollment	30 participants
Start Date	2024-12-01
Primary Completion	2025-12 (estimated)
Study Completion	2026-04 (estimated)
Updated on ClinicalTrials.gov	2025-03-18